ATR/CHEK1基因突变与胃癌高TMB/MSI-H状态的关系及其对免疫治疗效果的预测作用
雒雯宇 , 任静怡 , 艾力菲娅·依力夏提 , 申情 , 宋娜
中国医科大学学报 ›› 2026, Vol. 55 ›› Issue (9) : 802 -806.
ATR/CHEK1基因突变与胃癌高TMB/MSI-H状态的关系及其对免疫治疗效果的预测作用
Relationship between ATR/CHEK1 gene mutations and high TMB/MSI-H status in gastric cancer and their predictive role on immunotherapy efficacy
目的 探讨胃癌 (GC) 患者共济失调毛细血管扩张突变基因Rad3相关激酶 (ATR) 和检查点激酶1 (CHEK1) 基因突变与肿瘤突变负荷 (TMB)、微卫星状态 (MSS) 及程序性死亡配体1 (PD-L1) 表达的相关性,评估其作为预测免疫治疗效果生物标志物的潜力。方法 回顾性分析594例GC患者的福尔马林固定石蜡包埋组织样本,利用下一代测序技术检测ATR/CHEK1基因突变、TMB和MSS,并通过免疫组织化学检测PD-L1表达。采用Fisher确切概率法、χ2检验、Wilcoxon秩和检验和Spearman相关分析评估变量间的关联性。结果 在594例患者中,检出ATR突变22例 (3.7%),其中3例同时携带CHEK1突变 (0.5%)。ATR突变患者中,高肿瘤突变负荷 (TMB-H) 比例 (63.6%) 和高度微卫星不稳定 (MSI-H) 比例(57.1%) 显著增高。3例ATR/CHEK1双突变患者均为TMB-H和MSI-H,且双突变组的TMB值显著高于ATR单突变组 (P < 0.05)。突变位点分析显示,ATR基因I774Yfs*5移码突变在TMB-H (35.7%) 和MSI-H (41.7%) 患者中高频出现。ATR突变组中有27.3%的患者PD-L1联合阳性评分 (CPS) ≥1。结论 ATR/CHEK1基因突变,特别是双基因突变和I774Yfs*5热点突变,与GC的TMB-H和MSI-H状态相关,其可能通过破坏DNA损伤修复通路增强肿瘤免疫原性。ATR/CHEK1突变状态有望成为预测GC免疫治疗敏感性的新型生物标志物。
Objective To explore the correlations between mutations in ataxia telangiectasia and Rad3-related kinase (ATR) and checkpoint kinase 1 (CHEK1) genes and tumor mutational burden (TMB),microsatellite status (MSS),and programmed death-ligand 1 (PD-L1) expression in patients with gastric cancer (GC) and to evaluate their potential as biomarkers for predicting the efficacy of immunotherapy. Methods A total of 594 formalin-fixed paraffin-embedded tissue samples from patients with GC were retrospectively analyzed. Next-generation sequencing (NGS) was used to assess ATR/CHEK1 gene mutations,TMB,and MSS,and immunohistochemistry was performed to analyze PD-L1 expression. Fisher’s exact test,chi-square test,Wilcoxon rank-sum test,and Spearman correlation analysis were used to assess the associations among variables. Results Among the 594 enrolled patients,ATR mutations were identified in 22 patients (3.7%),including three concurrently harboring CHEK1 mutations (0.5%). Patients with ATR mutations had significantly higher proportions of high tumor mutational burden (TMB-H,63.6%) and microsatellite instability-high (MSI-H,57.1%). All three patients with concurrent ATR and CHEK1 double mutations presented TMB-H and MSI-H status,and the TMB level in the double mutation group was markedly higher than that in the ATR single mutation group (P < 0.05). Mutation site analysis revealed that the frameshift mutation I774Yfs*5 of the ATR gene occurred at a high frequency in patients with TMB-H (35.7%) and MSI-H (41.7%). In the ATR mutation group,27.3% of patients had a combined positive score (CPS) of PD-L1≥1. Conclusion This study confirmed that ATR/CHEK1 gene mutations,especially double mutations and the hotspot mutation I774Yfs*5,correlate with TMB-H and MSI-H status in GC,indicating that these mutations may enhance tumor immunogenicity by disrupting the DNA damage repair pathway. Collectively,ATR/CHEK1 mutation status can serve as a novel biomarker for predicting the sensitivity to immunotherapy in GC.
| [1] |
|
| [2] |
BRAY F,LAVERSANNE M,SUNG H, |
| [3] |
|
| [4] |
|
| [5] |
杨庆林,郭晓东,张睿, |
| [6] |
|
| [7] |
中国抗癌协会肿瘤精准治疗专业委员会. 二代测序技术在消化系统肿瘤临床应用的中国专家共识 [J]. 肿瘤综合治疗电子杂志, 2024,10 (1):69-92. DOI:10.1215/JMCM.2024.01-11. |
| [8] |
FRAMPTON GM,FICHTENHOLTZ A,OTTO GA, |
| [9] |
CHALMERS ZR,CONNELLY CF,FABRIZIO D, |
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
辽宁省科学技术计划(2021-MS-184)
/
| 〈 |
|
〉 |